{"article_link": "https://doi.org/10.1038/s41591-021-01329-2", "data": [{"id": "data_1", "omics": "Transcriptomics", "link": "https://covid19cellatlas.org/", "format": "h5ad", "source": "ArrayExpress", "public_id": "E-MTAB-10026"}, {"id": "data_2", "omics": "Proteomics", "link": "https://covid19cellatlas.org/", "format": "h5ad", "source": "Custom CITE-seq", "public_id": "E-MTAB-10026"}, {"id": "data_3", "omics": "Immunomics (TCR)", "link": "https://covid19cellatlas.org/", "format": "h5ad", "source": "10x Genomics", "public_id": "E-MTAB-10026"}, {"id": "data_4", "omics": "Immunomics (BCR)", "link": "https://covid19cellatlas.org/", "format": "h5ad", "source": "10x Genomics", "public_id": "E-MTAB-10026"}, {"id": "data_5", "omics": "Multi-omics", "link": "https://covid19cellatlas.org/", "format": "h5ad", "source": "Combined Transcriptomics, Proteomics, and Immunomics", "public_id": "E-MTAB-10026"}], "analyses": [{"id": "analysis_1", "analysis_type": "Single-cell transcriptome and surface proteome analysis", "analysis_data": ["data_1", "data_2"], "training_set": [], "test_set": [], "label": {"severity": ["healthy", "asymptomatic", "mild", "moderate", "severe", "critical"]}}, {"id": "analysis_2", "analysis_type": "Cell clustering and annotation", "analysis_data": ["data_1", "data_2", "data_3", "data_4"], "training_set": [], "test_set": [], "label": {"condition": ["healthy", "asymptomatic", "mild", "moderate", "severe", "critical"]}}, {"id": "analysis_3", "analysis_type": "Differential abundance testing", "analysis_data": ["data_1", "data_2", "data_3", "data_4"], "training_set": [], "test_set": [], "label": {"severity": ["healthy", "asymptomatic", "mild", "moderate", "severe", "critical"]}}, {"id": "analysis_4", "analysis_type": "Gene Set Enrichment Analysis (GSEA)", "analysis_data": ["data_1", "data_2", "data_3", "data_4"], "training_set": [], "test_set": [], "label": {"severity": ["healthy", "asymptomatic", "mild", "moderate", "severe", "critical"]}}, {"id": "analysis_5", "analysis_type": "Cydar analysis", "analysis_data": ["data_2"], "training_set": [], "test_set": [], "label": {"severity": ["healthy", "asymptomatic", "mild", "moderate", "severe", "critical"]}}, {"id": "analysis_6", "analysis_type": "TCR and BCR clonality analysis", "analysis_data": ["data_3", "data_4"], "training_set": [], "test_set": [], "label": {"gender": ["female", "male"], "severity": ["healthy", "asymptomatic", "mild", "moderate", "severe", "critical"]}}, {"id": "analysis_7", "analysis_type": "Interferon, TNF, and JAK–STAT response scoring", "analysis_data": ["data_1"], "training_set": [], "test_set": [], "label": {"severity": ["healthy", "asymptomatic", "mild", "moderate", "severe", "critical"]}}, {"id": "analysis_8", "analysis_type": "kBET analysis", "analysis_data": ["data_1", "data_2"], "training_set": [], "test_set": [], "label": {"batch_factor": ["Newcastle", "Cambridge", "London"]}}, {"id": "analysis_9", "analysis_type": "Bronchoalveolar lavage (BAL) data comparison", "analysis_data": ["data_1", "data_2"], "training_set": [], "test_set": [], "label": {"source": ["GSE145926"]}}, {"id": "analysis_10", "analysis_type": "CellPhoneDB receptor-ligand interaction analysis", "analysis_data": ["data_2"], "training_set": [], "test_set": [], "label": {"cell_type": ["monocytes", "platelets"]}}, {"id": "analysis_11", "analysis_type": "Platelet activation analysis", "analysis_data": ["data_2"], "training_set": [], "test_set": [], "label": {"condition": ["healthy", "asymptomatic", "mild", "moderate", "severe", "critical"]}}, {"id": "analysis_12", "analysis_type": "HSPC commitment scoring", "analysis_data": ["data_1", "data_2"], "training_set": [], "test_set": [], "label": {"severity": ["healthy", "asymptomatic", "mild", "moderate", "severe", "critical"]}}, {"id": "analysis_13", "analysis_type": "Multiplex cytokine analysis", "analysis_data": ["data_2"], "training_set": [], "test_set": [], "label": {"severity": ["healthy", "asymptomatic", "mild", "moderate", "severe", "critical"]}}, {"id": "analysis_14", "analysis_type": "Restimulation of PBMCs with SARS-CoV-2 peptide", "analysis_data": ["data_1", "data_2", "data_3"], "training_set": [], "test_set": [], "label": {"condition": ["healthy", "asymptomatic", "mild", "moderate", "severe", "critical"]}}, {"id": "analysis_15", "analysis_type": "Flow cytometry validation", "analysis_data": ["data_1", "data_2", "data_3"], "training_set": [], "test_set": [], "label": {"condition": ["healthy", "asymptomatic", "mild", "moderate", "severe", "critical"]}}, {"id": "analysis_16", "analysis_type": "Differential correlation analysis", "analysis_data": ["data_1", "data_2"], "training_set": [], "test_set": [], "label": {"condition": ["healthy", "asymptomatic", "mild", "moderate", "severe", "critical"]}}], "results": [{"analysis_id": "analysis_1", "metric": "Fold change", "value": "Clonally expanded CD8+ T cells: 1.81", "features": ["CD8+ T cells", "TE:EM ratio", "CD8+ TEM cells"]}, {"analysis_id": "analysis_2", "metric": "Clustering resolution", "value": "18 cell subsets and 27 cell states identified", "features": ["18 cell subsets", "27 cell states", "proliferating monocytes", "innate lymphoid cell subpopulations", "isotype-specific plasma cells"]}, {"analysis_id": "analysis_3", "metric": "Odds ratio", "value": "Clonally expanded CD8+ T cells: 1.81 (P=2.49×10⁻¹⁵); CD8+ TEM cells: 0.87 (P=0.26)", "features": ["Clonally expanded CD8+ T cells", "CD8+ TEM cells", "TE:EM ratio"]}, {"analysis_id": "analysis_4", "metric": "Normalized enrichment score (NES)", "value": "Significant enrichment in IL-2–STAT5, mTORC1, IFNγ, and IL-6–JAK–STAT3 pathways", "features": ["IL-2–STAT5 signaling", "mTORC1 signaling", "inflammatory response", "IFNγ response", "IL-6–JAK–STAT3 signaling"]}, {"analysis_id": "analysis_5", "metric": "Spatial FDR", "value": "<0.05", "features": ["608 hyperspheres", "B cells", "plasma cells", "HSPCs"]}, {"analysis_id": "analysis_6", "metric": "Clonotype size gini indices", "value": "Female: 0.87; Male: 0.71", "features": ["Clonotype size and diversity", "node closeness centrality", "IGHV1-46 gene usage in women with critical disease"]}, {"analysis_id": "analysis_7", "metric": "Normalized enrichment score (NES)", "value": "0.75", "features": ["Type I/III IFN response", "TNF signaling", "JAK–STAT response"]}, {"analysis_id": "analysis_8", "metric": "Wilcoxon paired signed-rank test", "value": "Improved rejection rate after integration (P < 2.1×10⁻⁸)", "features": ["Improved mixing of cells by site", "batch correction with Harmony"]}, {"analysis_id": "analysis_9", "metric": "Similarity score", "value": "High similarity between CD16+ monocytes and BAL macrophages", "features": ["FCGR3A", "C1QA/B/C", "type I IFN response genes"]}, {"analysis_id": "analysis_10", "metric": "Interaction strength", "value": "SIRPA:CD47, FPR1:ANXA1, FPR2:APP", "features": ["Platelet-monocyte interactions", "ICAM1"]}, {"analysis_id": "analysis_11", "metric": "Expression fold change", "value": "Platelet activation markers PF4, GP9, STXBP2", "features": ["Platelet activation", "CD34+ HSPCs"]}, {"analysis_id": "analysis_12", "metric": "P-value", "value": "2.92×10⁻¹⁸", "features": ["TE:EM ratio", "CD8+ T cell differentiation", "CD8+ TTE", "CD8+ TEM"]}, {"analysis_id": "analysis_13", "metric": "Cytokine levels", "value": "CCL4 (2-fold), CXCL10 (1.8-fold), IL-7 (1.5-fold), IL-1α (1.2-fold)", "features": ["CCL4", "CXCL10", "IL-7", "IL-1α"]}, {"analysis_id": "analysis_14", "metric": "Fold change", "value": "CD137 and CD107a upregulated in SARS-CoV-2 restimulation", "features": ["CD137", "CD107a", "CD8+ T cell activation"]}, {"analysis_id": "analysis_15", "metric": "Percentage of cells", "value": "50,000–60,000 cells per pool", "features": ["CD137", "CD107a", "CD8+ T cell activation"]}, {"analysis_id": "analysis_16", "metric": "Pearson correlation", "value": "0.8 (in mild/moderate), 0.4 (in severe/critical)", "features": ["TFH and plasmablast/plasma cell correlation", "loss in severe disease"]}]}